Hepatitis B Virus E Antigen (HBeAg) Antikörper (Alexa Fluor 750)

Produktnummer ABIN5004264

Produktdetails

Target: Hepatitis B Virus E Antigen (HBeAg)

Reaktivität: Hepatitis B Virus (HBV), Virus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Alexa Fluor 750

Applikation: Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Kreuzreaktivität: Virus

Kreuzreaktivität (Details): Hepatitis B Virus

Aufreinigung: Purified by Protein G.

Immunogen: HBeAg full length protein

Klon: 2E9

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: Hepatitis B Virus E Antigen (HBeAg)

Andere Bezeichnung: HBeAg (HBeAg Produkte)

Synonyme: precore; HBe antigen; PreC; HBeAg; precore protein; external core antigen; HBeAg; p25 antikoerper, C antikoerper

Substanzklasse: Viral Protein

Hintergrund:

Synonyms: Hepatitis B, Core antigen, Core protein, HBe antigen, HBeAg, HBVgp4, Pre C,C, Precore protein, Precore/core, Precore/core ORF, Precore/core protei, HBEAG_HBVD3, External core antigen, HBeAg, p25.

Background: Hepatitis B e-antigen (HBeAg) is a viral protein associated with HBV infections. Unlike the surface antigen, the e-antigen is found in the blood only when there are viruses also present. When the virus goes into hiding,? the e-antigen will no longer be present in the blood. HBeAg is often used as a marker of ability to spread the virus to other people (infectivity). Measurement of e-antigen may also be used to monitor the effectiveness of HBV treatment, successful treatment will usually eliminate HBeAg from the blood and lead to development of against e-antigen (anti-HBe). There are some types (strains) of HBV that do not make e-antigen, these are especially common in the Middle East and Asia. In areas where these strains of HBV are common, testing for HBeAg is not very useful.